Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | FAAH | O00519 | 5/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TERT | O14746 | 3/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | FABP4 | P15090 | 2/20 | 0.45 |
| ▸ | F7 | P08709 | 2/20 | 0.45 |
| ▸ | F3 | P13726 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19839030 | 0.98 | TSHR (0.62) | TSHRFAAHTRPV1MAPTKMT2A | |
| SCHEMBL19043647 | 0.98 | TSHR (0.62) | TSHRFAAHTRPV1MAPTKMT2A | |
| SCHEMBL4608945 | 0.98 | TSHR (0.62) | TSHRFAAHTRPV1MAPTKMT2A | |
| SCHEMBL30797404 | 0.98 | TSHR (0.62) | TSHRFAAHTRPV1MAPTKMT2A | |
| SCHEMBL27790330 | 0.95 | TSHR (0.65) | TSHRFAAHTRPV1MAPTKMT2A | |
| SCHEMBL23855776 | 0.93 | TSHR (0.70) | TSHRFAAHTRPV1MAPTKMT2A | |
| SCHEMBL3308698 | 0.93 | TSHR (0.70) | TSHRFAAHTRPV1MAPTKMT2A | |
| SCHEMBL5664979 | 0.93 | TSHR (0.70) | TSHRFAAHTRPV1MAPTKMT2A | |
| SCHEMBL22749396 | 0.93 | TSHR (0.70) | TSHRFAAHTRPV1MAPTKMT2A | |
| SCHEMBL21590063 | 0.93 | TSHR (0.70) | TSHRFAAHTRPV1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0162764-A1 | Composition and method for enhancing absorption of drugs from gastrointestinal tract using acylcarnitines | MERCK & CO. INC. (US) | 1985-11-27 | — | — | EP | claimed |
| CN-113164448-A | Amino acid anilines as small molecule modulators of IL-17 | 利奥制药有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-108025538-A | Multilayer structure making and its manufacture method, the packaging material obtained using it and the protection sheet material of product and electronic equipment | 株式会社可乐丽 | 2018-05-11 | — | — | CN | disclosed |
| CN-107402270-A | A kind of method of volatile organic matter VOCs and aldehyde ketone volatile quantity in measure automobile interior decoration materials | 通标标准技术服务(上海)有限公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-107000377-A | Multilayer structure and packaging material obtained using same | 株式会社可乐丽 | 2017-08-01 | — | — | CN | disclosed |
| CN-107000401-A | Multilayer structure, packaging material and product obtained using same, and protective sheet for electronic device | 株式会社可乐丽 | 2017-08-01 | — | — | CN | disclosed |
| EP-2642990-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL Business Plc. (GB) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012069790-A1 | THERAPEUTIC USE OF COMPOUNDS | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2012-05-31 | — | — | WO | disclosed |
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| WO-2005080376-A1 | SUBSTITUTED SPIRO AZABICYCLICS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-0162764-B1 | COMPOSITION AND METHOD FOR ENHANCING ABSORPTION OF DRUGS FROM GASTROINTESTINAL TRACT USING ACYLCARNITINES | MERCK & CO. INC. (US) | 1989-08-09 | — | — | EP | disclosed |
| US-4835138-A | Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities | MERCK & CO., INC. (US) | 1989-05-30 | — | — | US | disclosed |
| US-4822773-A | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts | MERCK & CO., INC. (US) | 1989-04-18 | — | — | US | disclosed |
| US-4729989-A | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts | MERCK & CO., INC. (US) | 1988-03-08 | — | — | US | disclosed |
| US-4692441-A | B-LACTAM ANTIBIOTICS | MERCK & CO., INC. (US) | 1987-09-08 | — | — | US | disclosed |
| EP-0214898-A2 | Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities | MERCK & CO. INC. (US) | 1987-03-18 | — | — | EP | disclosed |
| EP-0206947-A2 | Pharmaceutical composition containing choline ester salts for enhancing gastrointestinal tract absorption | MERCK & CO. INC. (US) | 1986-12-30 | — | — | EP | disclosed |
| EP-0162764-A1 | Composition and method for enhancing absorption of drugs from gastrointestinal tract using acylcarnitines | MERCK & CO. INC. (US) | 1985-11-27 | — | — | EP | disclosed |
| US-4537772-A | Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines | MERCK & CO., INC. (US) | 1985-08-27 | — | — | US | disclosed |
| US-4055438-A | TITANIA, ALUMINA, SILICA, TANTALUM OR ANTIMONY PENTOXIDE, MANGANESE OR COPPER | NGK INSULATORS, LTD. (JA) | 1977-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TIE1, KDR, FLT1 | TSHR 922/4885FAAH 2710/4885TRPV1 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.